New drug combo aims to boost stem cell transplant success for tough blood cancers
NCT ID NCT07044544
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This early-stage trial tests whether adding decitabine and venetoclax to a standard stem cell transplant is safe for people with high-risk blood cancers like leukemia. About 20 adults aged 18-75 with a matching donor will take part. The goal is to find the best dose that limits severe side effects while improving the transplant's ability to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.